InvestorsObserver
×
News Home

Should You Buy Affimed NV (AFMD) Stock on Wednesday?

Wednesday, September 21, 2022 01:02 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Affimed NV (AFMD) Stock on Wednesday?

The market has been down on Affimed NV (AFMD) stock recently. AFMD gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Affimed NV has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AFMD!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With AFMD Stock Today?

Affimed NV (AFMD) stock has fallen -3.11% while the S&P 500 has risen 0.49% as of 12:48 PM on Wednesday, Sep 21. AFMD is down -$0.06 from the previous closing price of $2.09 on volume of 411,499 shares. Over the past year the S&P 500 has fallen -11.08% while AFMD is down -67.78%. AFMD lost -$0.60 per share in the over the last 12 months. To screen for more stocks like Affimed NV click here.

More About Affimed NV

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany. Click Here to get the full Stock Report for Affimed NV stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App